Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation & Amortization (CF) (2022 - 2025)

Axsome Therapeutics' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $114000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 11.63% year-over-year to $114000.0; the TTM value through Dec 2025 reached $503000.0, down 5.45%, while the annual FY2025 figure was $503000.0, 5.45% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $114000.0 at Axsome Therapeutics, down from $120000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $149000.0 in Q1 2025 and bottomed at $37000.0 in Q1 2022.
  • The 4-year median for Depreciation & Amortization (CF) is $120000.0 (2025), against an average of $109812.5.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 143.24% in 2023 before it decreased 14.29% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $85000.0 in 2022, then skyrocketed by 56.47% to $133000.0 in 2023, then fell by 3.01% to $129000.0 in 2024, then decreased by 11.63% to $114000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Depreciation & Amortization (CF) are $114000.0 (Q4 2025), $120000.0 (Q3 2025), and $120000.0 (Q2 2025).